Edition:
United Kingdom

Cerecor Inc (CERC.OQ)

CERC.OQ on NASDAQ Stock Exchange Capital Market

4.40USD
23 Feb 2018
Change (% chg)

$0.35 (+8.64%)
Prev Close
$4.05
Open
$4.08
Day's High
$4.52
Day's Low
$4.06
Volume
75,053
Avg. Vol
105,761
52-wk High
$4.52
52-wk Low
$0.34

Chart for

About

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $28.92
Shares Outstanding(Mil.): 26.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Cerecor To Acquire Avadel Pharmaceuticals' Pediatric Assets

* CERECOR TO ACQUIRE AVADEL PHARMACEUTICALS' PEDIATRIC ASSETS

12 Feb 2018

BRIEF-Cerecor announces leadership changes

* Cerecor Inc - ‍Interim Chief Executive Officer John Kaiser and Chief Medical Officer Dr. Ronald Marcus stepping down​

17 Nov 2017

BRIEF-Cerecor acquires TRX Pharmaceuticals

* Cerecor Inc - ‍Under terms of transactions, Cerecor will make an initial payment of $23 million for purchase of TRX​

17 Nov 2017

BRIEF-Cerecor reports Q3 earnings per share of $0.52

* As of Sept 30, cash and cash equivalents were $24.0 million, escrowed cash receivable was $3.75 million and current liabilities were $4.8 million​

06 Nov 2017

Earnings vs. Estimates